Title: Vical Announces News Release and Conference Call Schedule for
First Quarter 2007 Financial Results Date: 4/26/2007 6:30:00 AM
SAN DIEGO, April 26 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today
announced that the company will report financial results for the quarter ended March 31,
2007, before the opening of trading on Thursday, May 3, and conduct a conference call and
webcast to discuss the financial results and provide a company update at noon Eastern Time
on Thursday, May 3. The call is open on a listen-only basis to any interested parties. The
company will provide details on independent and partnered development programs in the
conference call and webcast.
To listen to the conference call, dial (888) 224-3260, or (913) 905-1086 for
international participants. A replay of the call will be available for 48 hours beginning
about two hours after the call. To listen to the replay, dial (888) 203-1112, or (719)
457-0820 for international participants, and enter conference identification number
1970742. The call also will be available live and archived through the events page at
www.vical.com.
Invited analysts and institutional investors may ask questions during the conference
call. Others may submit questions before the call by e-mail addressed to info@vical.com or
by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and
general interest. Selected questions received with sufficient notice before the call will
be answered as time permits at the end of the call. For further information, contact
Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at
info@vical.com.
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA
delivery technologies for the prevention and treatment of serious or life-threatening
diseases. Potential applications of the company's DNA delivery technology include DNA
vaccines for infectious diseases or cancer, in which the expressed protein is an
immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system
stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic
growth factor. The company is developing certain infectious disease vaccines and cancer
therapeutics internally. In addition, the company collaborates with major pharmaceutical
companies and biotechnology companies that give it access to complementary technologies or
greater resources. These strategic partnerships provide the company with mutually
beneficial opportunities to expand its product pipeline and address significant unmet
medical needs. Additional information on Vical is available at www.vical.com.
This press release contains forward-looking statements subject to risks and
uncertainties that could cause actual results to differ materially from those projected.
Forward-looking statements include statements about the company's focus, collaborative
partners, product candidates, and developmental status. Risks and uncertainties include
whether any product candidates will be shown to be safe and efficacious in clinical
trials, the timing of clinical trials, whether Vical or its collaborative partners will
seek or gain approval to market any product candidates, the dependence of the company on
its collaborative partners, and additional risks set forth in the company's filings with
the Securities and Exchange Commission. These forward-looking statements represent the
company's judgment as of the date of this release. The company disclaims, however, any
intent or obligation to update these forward-looking statements.
Contacts: Investors: Media:
Alan R. Engbring Susan Neath
Vical Incorporated Porter Novelli Life Sciences
(858) 646-1127 (619) 849-6007
Website: www.vical.com
SOURCE Vical Incorporated
-0- 04/26/2007
/CONTACT: Investors, Alan R. Engbring of Vical Incorporated,
+1-858-646-1127; or Media, Susan Neath of Porter Novelli Life Sciences,
+1-619-849-6007, for Vical Incorporated/
/Web site: http://www.vical.com /
(VICL)
CO: Vical Incorporated
ST: California
IN: HEA MTC BIO
SU: CCA MAV
SF-KA
-- LATH012 --
5370 04/26/2007 06:30 EDT http://www.prnewswire.com
|